BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 12731338)

  • 1. [Antilipemic therapy and rhabdomyolysis].
    Paragh G; Balogh Z; Romics L
    Orv Hetil; 2003 Mar; 144(11):515-20. PubMed ID: 12731338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
    Jones PH; Davidson MH
    Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics.
    Landesman KA; Stozek M; Freeman NJ
    Conn Med; 1999 Aug; 63(8):455-7. PubMed ID: 10500341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.
    Kind AH; Zakowski LJ; McBride PE
    WMJ; 2002; 101(7):53-6. PubMed ID: 12426921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
    Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L
    Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal rhabdomyolysis caused by lipid-lowering therapy.
    Federman DG; Hussain F; Walters AB
    South Med J; 2001 Oct; 94(10):1023-6. PubMed ID: 11702815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
    Zeman M; Zák A; Vecka M; Romaniv S
    Cas Lek Cesk; 2003 Aug; 142(8):500-4. PubMed ID: 14626567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for statin-associated rhabdomyolysis.
    Schech S; Graham D; Staffa J; Andrade SE; La Grenade L; Burgess M; Blough D; Stergachis A; Chan KA; Platt R; Shatin D
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):352-8. PubMed ID: 16892458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin-fibrate combination therapy.
    Shek A; Ferrill MJ
    Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
    Ozdemir O; Boran M; Gökçe V; Uzun Y; Koçak B; Korkmaz S
    Angiology; 2000 Aug; 51(8):695-7. PubMed ID: 10959522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].
    Sirvent AE; Cabezuelo JB; Enríquez R; Amorós F; González C; Reyes A
    Nefrologia; 2001; 21(5):497-500. PubMed ID: 11795020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
    Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
    Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myotoxicity and rhabdomyolisis due to statins].
    Banga JD
    Ned Tijdschr Geneeskd; 2001 Dec; 145(49):2371-6. PubMed ID: 11770264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Jamal SM; Eisenberg MJ; Christopoulos S
    Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myotoxicity associated with lipid-lowering drugs.
    Baer AN; Wortmann RL
    Curr Opin Rheumatol; 2007 Jan; 19(1):67-73. PubMed ID: 17143099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen.
    Marsà Carretero M; Alos Manrique C; Valles Callol JA
    Br J Gen Pract; 2002 Mar; 52(476):235-6. PubMed ID: 12030671
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy, and drug combinations.
    Lavie CJ
    Am J Geriatr Cardiol; 2004; 13(3 Suppl 1):29-33. PubMed ID: 15133427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.